Skip to main content

Table 1 Profile of study patients and baseline clinical features

From: Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy

Characteristic

70R

70Q/H

P

Demographic data

   

 Number

89

23

 

 Gender (M/F)

52/37

12/11

0.589a

 Age (years)

44.8 (8.9)

46.9 (11.0)

0.344b

 History of blood transfusionc

40 (44.9 %)

12 (52.2 %)

0.535a

Laboratory data

   

 Serum alanine aminotransferase (IU/L)

57.5 (24.6)

56.5 (20)

0.867b

 Serum aspartate aminotransferase (IU/L)

40.3 (16.9)

37.9 (16.0)

0.540b

 Total serum bilirubin (μmol/L)

17.0 (9.1)

18.6 (12.1)

0.476b

 Serum albumin (g/L)

39.6 (5.7)

38.0 (6.1)

0.241b

 γ-Glutamyl transpeptidase (IU/L)

41.9 (18.0)

40.3 (21.4)

0.725b

 Triglycerides (mmol/L)

1.1 (0.5)

1.0 (0.49)

0.427b

 Total cholesterol (mmol/L)

4.4 (0.57)

4.4 (0.71)

0.934b

 Prothrombin time (INR)

1.01 (0.18)

1.04 (0.24)

0.495b

 Prothrombin activity (%)d

91.4 (15.9)

86.3 (16.7)

0.178b

 Leukocyte count (109/L)

4.75 (1.48)

4.17 (1.0)

0.082b

 Platelet count ( 109/L)

154.2 (66.2)

140.2 (72.4)

0.379b

 Hemoglobin (g/L)

135.7 (17.1)

129.8 (22.8)

0.172b

 HCV RNA level (log10 IU/mL)

6.31 (0.66)

6.28 (0.86)

0.873b

IL28B genotype

   

 rs12979860

77CC/12CT

15CC/8CT

0.038e

 rs8099917

78TT/11TG

15TT/8TG

0.025e

  1. Normal reference ranges: 5–40 IU/L for alanine aminotransferase; 8–40 IU/L for aspartate aminotransferase; 5–20 μmol/L for total serum bilirubin; 36–55 g/L for serum albumin; 10–50 IU/L for γ-Glutamyl transpeptidase; 0.22–1.69 mmol/L for triglycerides; 3.9–5.7 mmol/L for cholesterol; 0.8–1.5 INR for prothrombin time; 80–120 % for prothrombin activity; 4–10 × 109/L for leukocyte count; 100–300 × 109/L for platelet count; 110–160 g/L for hemoglobin
  2. aPearson Chi-Square Test
  3. bIndependent-Samples T Test
  4. Data are the mean (standard deviation) values, except those denoted by c, which represent the number (percentage) of patients
  5. dProthrombin activity (PTA) was calculated by the patient prothrombin time (PPT) and control prothrombin time (CPT) according to the following formula: PTA = [CPT-(CPT × 0.6)]/[PPT-(CPT × 0.6)] × 100 %
  6. eContinuity Correction Chi-Square Test